Clinical Trials Logo

PVR clinical trials

View clinical trials related to PVR.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02865031 Completed - PVR Clinical Trials

Dacorin for Proliferative Vitreoretinopathy

Dacorin
Start date: August 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Purpose: To determine the safety, tolerability, and efficacy of human recombinant decorin protein, a transforming growth factor ß (TGFß) inhibitor in preventing proliferative vitreoretinopathy (PVR) in patients with perforating globe injuries. Methods: This is a prospective, single-center, open-label, interventional case series. A single intravitreal injection of decorin 200ug (n=4) and 400ug (n=8) was given within 24 hours of injury. Pars plana vitrectomy with silicone oil injection was done if indicated. ERG was done before injections, at day 10, and 3 months. Serial plasma decorin levels were assessed before injections, day 3, 5, and 10 post-injection. Clinical assessment included globe survival, retinal attachment rate, and PVR evaluation.